$EXOZ News

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program

EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

eXoZymes Q4 Earnings Call Highlights

eXoZymes Provides Fourth Quarter and Full Year 2025 Update

eXoZymes Inc. - Common Stock Q4 EPS $(0.31)

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation

Reported Earlier, eXoZymes Achieves High Conversion Yield And 99.6% Purity In Initial NCT Pilot Run Advancing Commercial Readiness

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

Exozymes Files Prospectus To Offer Up To $50M Securities

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

EXoZymes Inc (EXOZ) Q3 2025 Earnings Call Highlights: Unlocking Market Opportunities Amid ...

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff

eXoZymes Inc. - Common Stock Q3 EPS $(0.27)

eXoZymes Inc. - Common Stock Q3 EPS $(0.27)

eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST

CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference